Company / Shareholders' Equity
MoonLake Immunotherapeutics Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$304.5M
FY2025
5-year range
-$11.6M / $513.5M
FY2021-FY2025
Trend
-31.9%
vs FY2024
Sector context
#132 of 213
Health Care
What the data says
At $304M, MoonLake Immunotherapeutics's shareholders' equity ranks #132 of 213 in the Health Care sector. Declined from $513M to $304M over the past 2 years.
Based on SEC 10-K filings.
$304M in FY2025 with a 3-year CAGR of +64.2%.
Declined from $513M to $304M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +64.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#132 of 213 in Health CareTop 62% of 213This company $304.5M Sector average $2.5B
▼
-88.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +64.2%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 31.9% year-over-year.
- Ranks #132 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $304.5M | -31.9% |
| FY2024 | $446.8M | -13.0% |
| FY2023 | $513.5M | +646.7% |
| FY2022 | $68.8M | +690.5% |
| FY2021 | -$11.6M | -362.8% |
| FY2020 | -$2.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026